Negative symptoms of schizophrenia: the conceptualization and pathophysiological mechanisms. Part 1
https://doi.org/2618-6667-2018-77-86-96
Abstract
The conceptualization of negative symptoms has evolved in recent years; it is largely recognized that negative symptoms may be primary (related to the disease process) or secondary to other factors (i.e. positive symptoms, depression, side effects of drug treatment) and cluster in two dimensions: avolition (including amotivation, anhedonia and asociality) and defcit of expression (including affective flattening and alogia) that might have a different impact on functional outcome.
About the Author
Alexey Pavlichenko
A.I. Jevdokimov Moscow State University of Medicine and Dentistry, Moscow
Russian Federation
PgD, MD, assistant professor
Russian Federation
PgD, MD, assistant professor
References
1. Crow T.J. Positive and negative schizophrenia symptoms and the role of dopamine. The British Journal of Psychiatry. 1981;139(3):251– 254. doi: 10.1192/bjp.139.3.251
2. Mäkinen J., Miettunen J., Isohanni, M., Koponen, H. Negative symptoms in schizophrenia: A review. Nordic Journal of Psychiatry. 2008;62(5):334–341. doi :10.1080/08039480801959307
3. Pogue-Geile M.F., & Zubin J. Negative symptomatology and schizophrenia: A conceptual and empirical review. International Journal of Mental Health. 1987;16(4):3–45. doi: 10.1080/00207411.1 987.11449074
4. Galderisi S., Mucci A., Bitter I., Libiger J., Bucci P., Fleischhacker W., for the EUFEST Study Group. Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology. 2013;23(3):196–204. doi: 10.1016/j.euroneuro.2012.04.019
5. Chen L., Johnston J.A., Kinon B.J., Stauffer V., Succop P., Marques T.R., Ascher-Svanum H. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry. 2013;13(1). doi: 10.1186/1471-244x- 13-320
6. Cornblatt B., Obuchowski M. The hillside study of risk and early detection in schizophrenia: Early findings. Schizophrenia Research. 1998;29(1–2):10. doi: 10.1016/s0920-9964(97)88309-0
7. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS Consensus Statement on Negative Symptoms. Schizophrenia Bulletin. 2006;32(2):214–219. doi: 10.1093/schbul/ sbj053
8. Carpenter Jr.W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry. 1988;145(5):578–583. doi: 10.1176/ajp.145.5.578
9. Galderisi S., Färden A., Kaiser S. Dissecting negative symptoms of schizophrenia: History, assessment, pathophysiological mechanisms and treatment. Schizophrenia Research. 2017;186:1–2. doi: 10.1016/j.schres.2016.04.046
10. Buchanan R.W. Persistent negative symptoms in schizophrenia: An overview. Schizophrenia Bulletin. 2007;33(4):1013–1022. doi: 10.1093/ schbul/sbl057
11. Galderisi S., Bucci P., Mucci A., Kirkpatrick B., Pini S., Rossi A., Maj M. Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome. Schizophrenia Research. 2013;147(1):157–162. doi: 10.1016/j. schres.2013.03.020
12. Couture S.M., Granholm E.L., Fish S.C. A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia. Schizophrenia Research. 2011;125(2–3):152–160. doi: 10.1016/j. schres.2010.09.020
13. Galderisi S., Rossi A., Rocca P., Bertolino A., Mucci A., Bucci P. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014;13(3):275–287. doi: 10.1002/ wps.20167
14. Strassnig M.T., Raykov T., O’Gorman C., Bowie C.R., Sabbag S., Durand D., Harvey P.D. Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. Schizophrenia Research. 2015; 165(1):76–82. doi: 10.1016/j.schres.2015.03.033
15. Stahl S.M., Buckley P.F. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr. Scand. 2007; Jan;115(1):4–11.
16. Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.A., Daniel D.G., Cienfuegos A., Marder S.R. The Brief Negative Symptom Scale: Psychometric properties. Schizophrenia Bulletin. 2010;37(2):300–305. doi: 10.1093/schbul/sbq059
17. Kring A.M., Gur R.E., Blanchard J.J., Horan W.P., Reise S.P. The Clinical Assessment Interview for Negative Symptoms (CAINS): Final development and validation. American Journal of Psychiatry. 2013;170(2):165–172. doi: 10.1176/appi.ajp.2012.12010109
18. Lyne J., Renwick L., O’Donoghue B., Kinsella A., Malone K., Turner N., Clarke M. Negative symptom domain prevalence across diagnostic boundaries: The relevance of diagnostic shifts. Psychiatry Research. 2015;228(3):347–354. doi: 10.1016/j.psychres.2015.05.086
19. Kirkpatrick B. Developing concepts in negative symptoms. The Journal of Clinical Psychiatry. 2014;75(suppl. 1):3–7. doi: 10.4088/ jcp.13049su1c.01
20. Chen L., Johnston J.A., Kinon B.J., Stauffer V., Succop P., Marques T.R., Ascher-Svanum H. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry. 2013;13(1). doi: 10.1186/1471-244x- 13-320
21. Kelley M.E., van Kammen D.P., Allen D.N. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am. J. Psychiatry. 1999;156:406–411.
22. Tandon R., DeQuardo J.R. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr. Res. 2000;45:191–201.
23. Siris S.G., Addington D., Azorin J.-M., Falloon I. R., Gerlach J., Hirsch S.R. Depression in schizophrenia: recognition and management in the USA. Schizophrenia Research. 2001;47(2–3):185–197. doi: 10.1016/s0920-9964(00)00135-3
24. Kuck J., Zisook S. Negative symptomatology in schizophrenic outpatients. The Journal of Nervous and Mental Disease. 1992;180(8):510–515. doi: 10.1097/00005053-199208000-00006
25. Lanсon C. Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). Journal of Affective Disorders. 2000; 58(2):107–115. doi: 10.1016/s0165-0327(99)00075-0
26. Siris S.G. Depression in schizophrenia: perspective in the era of «atypical» antipsychotic agents. Am. J. Psychiatry. 2000;157:1379– 1389.
27. Lako I.M., Bruggeman R. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J. Affect. Disord. 2012;140:38–47. doi: 10.1016/j.jad.2011.10.014
28. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry. 2008;14(4):429–447. doi: 10.1038/sj.mp.4002136
29. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthøj B., Gattaz W.F. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry. 2015;16(3):142–170. doi: 10.3109/15622975.2015.1009163
30. Pani L., Gessa G.L. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Molecular Psychiatry. 2002;7(3):247–253. doi: 10.1038/sj.mp.4001040
31. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer, B. A., Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophrenia Bulletin. 2009;36(1):71–93. doi: 10.1093/schbul/sbp116
32. Park C.-H., Park T.-W., Yang J.C., Lee K.-H., Huang G.-B., Tong Z., Chung Y.-C. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol. International Clinical Psychopharmacology. 2012;27(2):114–120. doi: 10.1097/yic.0b013e3283502773
33. Fusar-Poli P., Papanastasiou E., Stahl D., Rocchetti M., Carpenter W., Shergill S., McGuire P. Treatments of negative symptoms in schizophrenia: Meta-analysis of 168 randomized placebo-controlled trials. Schizophrenia Bulletin. 2014;41(4):892–899. doi: 10.1093/schbul/sbu170
34. Peralta V., Cuesta M.J., Martinez-Larrea A., Serrano J.F. Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment. American Journal of Psychiatry. 2000;157(9):1461–1466. doi: 10.1176/ appi.ajp.157.9.1461
35. Kirschner M., Aleman A., Kaiser S. Secondary negative symptoms: A review of mechanisms, assessment and treatment. Schizophrenia Research. 2017;186:29–38. doi: 10.1016/j.schres.2016.05.003
36. Fervaha G., Takeuchi H., Lee J., Foussias G., Fletcher P. J., Agid O., Remington G. Antipsychotics and amotivation. Neuropsychopharmacology. 2015;40(6):1539–1548. doi: 10.1038/npp.2015.3
37. Takeuchi H., Suzuki T. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr. Bull. 2013;39:993–998.
38. Oshima I., Mino Y. Effects of environmental deprivation on negative symptoms of schizophrenia: a nationwide survey in Japan’s psychiatric hospitals. Psychiatry Res. 2005;136:163–171. doi. org/10.1016/j.psychres.2005.06.001
39. Nordentoft M., Welcher B., Knudsen H.C., Krasnik A., Jessen-Petersen B., Treufeldt P. CCPP-Copenhagen Community Psychiatric Project. Social Psychiatry and Psychiatric Epidemiology. 1996;31(6):336–344. doi: 10.1007/bf00783422
40. Elis O., Caponigro J.M., Kring, A.M. Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions. Clinical Psychology Review. 2013;33(8):914–928. doi: 10.1016/j.cpr.2013.07.001
41. Rovai L., Maremmani A.G. Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse. Riv. Psichiatr. 2013;48:1–9. doi: 10.1708/1228.13610
42. Garfield J.B.B., Lubman D.I., Yücel M. Anhedonia in substance use disorders: A systematic review of its nature, course and clinical correlates. Australian & New Zealand Journal of Psychiatry. 2013;48(1):36–51. doi: 10.1177/0004867413508455.
Review
For citations:
Pavlichenko A. Negative symptoms of schizophrenia: the conceptualization and pathophysiological mechanisms. Part 1. Psychiatry (Moscow) (Psikhiatriya). 2018;1(77):86-96. (In Russ.) https://doi.org/2618-6667-2018-77-86-96
Views:
2056
Email this article 
